Surgical Options for PSM from Colorectal Carcinoma: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Mihai Adrian Eftimie
,
Gheorghe Potlog
,
Sorin Tiberiu Alexandrescu

Peritoneal dissemination is proven to worsen the prognosis of these patients. Cytoreductive surgery (CRS), along with systemic chemotherapy, have been shown to constitute a survival benefit in selected patients with PSM. Furthermore, the association of CRS with hyperthermic intraperitoneal chemotherapy (HIPEC) seems to significantly improve the prognosis of patients with certain types of digestive malignancies associated with PSM. 

  • peritoneal surface metastases
  • digestive cancers
  • colorectal cancer

1. Epidemiology

CRC is the third most common type of cancer and generates the second most frequent cancer-related mortality globally. When diagnosed at an early stage, 70–80% of patients will benefit from a curative-intent surgical procedure, resulting in a 5-year survival rate of 72–93% for stages I–II [1].
For CRC, synchronous PSM is encountered in 6–7% of patients and almost half of them have peritoneal-only metastases [2]. Furthermore, the risk for metachronous PSM can be as high as 6% [3]. The literature reveals that an advanced T stage, the presence of positive lymph nodes, synchronous ovarian metastases, a poor differentiation of the primary tumor, a colonic versus a rectal origin, the R1/R2 resection of the primary tumor, the histologic type of mucinous or signet-ring adenocarcinoma, the perforation or stenosis of the primary tumor, and younger age are the most frequently reported risk factors for the development of metachronous PSM [3][4][5].

2. Treatment Options

Patients with PSM of colorectal origin have classically been treated only with systemic palliative oncologic therapy, and sometimes palliative surgery [1]. In patients who receive only palliative treatment, colorectal PSM is associated with a worse prognosis compared to non-peritoneal metastases (16.3 months for PSM vs. 19.1 months for liver-only metastases and 24.6 months for lung-only metastases [6][7].
In 2003, Verwaal et al. [8] published a Dutch phase 3 controlled trial comparing the OS rates achieved by CRS plus HIPEC vs. palliative surgery plus systemic chemotherapy in patients operated for bowel obstruction. They showed that the OS rates achieved by CRS plus HIPEC were significantly superior to those observed in patients treated with palliative surgery. Later on, many clinical protocols of CRS and HIPEC were evaluated in different high-volume centers to treat the patients with colorectal PSM. Thus, Elias D., Koga S., Quenet S. et al. [7][9][10][11] reported promising results for CRS and HIPEC when a macroscopically complete resection is performed (CC-0), with an average median OS of 40 months. In 2013, Goere D et al. [12] stated that, in specialized centers, CRS and HIPEC could even achieve a cure in one sixth of the patients who underwent a CC-0 resection, reporting 5-year disease free survival (DFS) rates of 16% in such patients. However, because all of these studies were retrospective, no definitive conclusions could be drawn, and most guidelines continued to recommend only palliative oncologic therapy in patients with PSM of colorectal origin, irrespective of the extent of peritoneal involvement.
To overcome this drawback, between February 2008 and January 2014, 265 patients were randomly assigned to CRS and HIPEC (133 patients) or to CRS alone (132 patients) in a randomized, open-label, phase 3 trial performed at 17 cancer centers in France (PRODIGE 7 trial). All patients were confirmed with CRC and PSM, had a PCI ≤ 25, a WHO performance status of 0 or 1, normal liver function, proper hematological function, and were eligible to receive chemotherapy for 6 months [13]. Any previous treatments were permitted, a 4-week wash-out period was indicated, and the main exclusion criteria were extraperitoneal metastases, previous HIPEC treatment, and grade 3 or worse peripheral neuropathy. For patients enrolled in the CRS plus HIPEC arm, the HIPEC technique was performed either in a closed or open abdomen manner, according to each center’s approach. Systemic chemotherapy (400 mg/m2 fluorouracil and 20 mg/m2 folinic acid) was administered intravenously 20 min before HIPEC (bidirectional chemotherapy protocol) and intraperitoneal chemotherapy consisted of oxaliplatin at a dose of 460 mg/m2 (for the open technique) or 360 mg/m2 (for the closed abdomen technique). Oxaliplatin was delivered intraperitoneally in 2 L/m2 of dextrose, heated at 43 °C, for 30 min. The follow-up was conducted one month after surgery, every 3 months for the first 3 years and every 6 months up to 5 years. The median OS was 41.7 months in the CRS plus HIPEC group and 41.2 months in the CRS alone group (p = 0.99). Although PRODIGE 7 did not reveal a survival benefit for the addition of HIPEC to CRS, this trial reported unexpectedly high OS rates in patients treated with CRS alone. These findings suggest that the completeness of CRS is the most important factor for survival in patients with PSM from CRCs, with similar observations already being reported by other authors in retrospective studies [8][10][14]. Furthermore, median relapse-free survival (RFS) between the two groups was not significantly different and 15% of patients in each group were considered cured at 5 years. According to the data of the PRODIGE 7 trial, CRS alone should be the cornerstone of therapeutic strategies with curative intent for colorectal peritoneal metastases [8], and the benefit of HIPEC is still debatable.

3. Prognostic Factors in Patients Treated with CRS +/− HIPEC

The only significant survival difference between the two study arms of the PRODIGE 7 trial was found in the subgroup of patients with a PCI between 11 and 15. In these patients, CRS and HIPEC were associated with significantly higher RFS rates than CRS alone, although the OS rates were similar among the two study arms. This might be the basis for further studies aiming to evaluate a potential survival benefit offered by CRS plus HIPEC vs. CRS alone in patients with more extensive PSM involvement.
Moreover, the cut-off value of the PCI associated with a significantly higher survival benefit after CRS + HIPEC has not been uniformly reported by different authors. Thus, Gustave Roussy’s group revealed that the maximum survival benefit of CRS plus HIPEC was achieved in patients with a PCI ≤ 10. [12] The Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in CRC patients in the United States, published in 2014 [15], state that CRS is particularly effective in patients with a low-volume peritoneal disease, suggesting that a PCI ≤ 12 and no evidence of systemic disease are the main prognostic factors for better survival. Yan TD [16] stated that patients with a PCI ≤ 13 had a better life expectancy. Authors such as Da Silva and Sugarbaker [17] set the limit of the PCI at 20. This value is also supported by data from Cavaliere et al. [18] and Van Sweringen et al. [19], whose data indicated that a PCI > 20 is associated with decreased survival rates, hence, they concluded that such patients should not be seen as candidates for CRS +/− HIPEC.
In and by itself, the PCI cannot predict unresectability for certain tumor locations [20]. Thus, some studies have suggested that the number of regions affected by PSM of colorectal origin and invasion of the small bowel in more than two different parts are independent prognostic factors for both unresectability and shorter survival [21][22]. A paper published by Elias D. et al. [23] in 2014 also revealed that the involvement of the lower ileum and a high PCI were negative prognostic factors for the efficacy of the multimodality treatment, while Verwaal et al. [8] demonstrated a clear decrease in the survival rates in patients with PSM involving six or more regions (p < 0.0001).
Alongside the CC score, the PCI, and the number of regions with PSM, other studies have suggested additional prognostic factors that were independently associated with OS and/or DFS in patients who underwent CRS +/− HIPEC for PSM of colorectal origin. However, the impact of these additional prognostic factors is still controversial, since most of the data are from relatively small retrospective studies. For example, Tonello M. et al. [24] found that operated patients with PSM of rectal origin had a worse prognosis than those with PSM of colonic origin. Hence, they proposed a more restrictive use of CRS and HIPEC in patients with PSM of rectal origin. The impact of the location of the primary tumor on OS in patients with PSM of colorectal origin was also assessed by Peron et al. [25] in a prospective study that included 796 patients undergoing complete CRS (CC-0) between January 2004 and January 2017 in 14 institutions from France (the BIG-RENAPE database) and two institutions from Canada. They revealed that the primary site had no impact on the long-term outcomes of patients with PSM undergoing a complete CRS. No impact on OS and DFS was encountered across all subgroups of patients. Researchers also found no impact of RAS and BRAF mutations on the outcomes after complete CRS. This evidence suggests that the side of the primary tumor should not represent an exclusion criterion for patients with PSM from colorectal origin that are amenable to CRS (with or without HIPEC). Similar results were reported by Massalou et al. [26], who found that the location of the primary tumor location as well as RAS and BRAF status had no significant impact on the OS or DFS. In their study, the only pathologic/molecular factors associated with worse OS after CRS + HIPEC were the signet ring and mucinous type of carcinoma, while the presence of microsatellite sequence stability (MSS) was associated with lower DFS rates. Researchers also found that BMI > 25 was associated with significantly lower OS and DFS rates.

4. Morbidity and Mortality after CRS +/− HIPEC

Higher BMI is also correlated with increased postoperative morbidity and mortality rates in colorectal procedures including CRS with or without HIPEC [27][28]. Regarding the 30-day mortality rates after CRS with/without HIPEC, most studies reported an average value of 2% [10][11][13][29]. In the PRODIGE 7 trial, there was no statistically significant difference (p = 0.083) concerning the frequency of grade 3 or worse adverse events at 30 days between the CRS alone group (32%) and the CRS + HIPEC group (42%) [8]. Similarly, Foster et al. [30] used the data from the American College of Surgeons National Surgical Quality Improvement Project database and found that CRS and HIPEC were associated with perioperative and 30-day postoperative morbidity and mortality rates similar to those of other oncological surgical procedures. However, the PRODIGE 7 trial showed a significantly increased 60-day rate of grade 3 or worse complication in the CRS plus oxaliplatin-based HIPEC group vs. the CRS alone group (26% vs. 15%, respectively; p = 0.035) [8]. This indicates that patients in the CRS + HIPEC group have a longer period of risk for developing complications, leading to a prolonged time to resumption of postoperative systemic chemotherapy. The lack of survival benefit and the significantly higher rate of grade 3 or worse adverse events at 60 days in the CRS + HIPEC group (vs. CRS alone group) seem to be reasonable arguments to refute the use of prophylactic HIPEC in patients with non-metastatic CRC at risk of developing PSM [13].

5. HIPEC Protocol

Although the PRODIGE 7 randomized controlled trial did not find any survival benefit from the association of HIPEC to CRS in patients with PSM of colorectal origin, its results were critically appraised by many authors including Paul H. Sugarbaker [31]. The major criticism of the PRODIGE 7 trial was related to the HIPEC protocol, concerning both the dose and the duration of chemotherapy.
In the PRODIGE 7 trial, the oxaliplatin-based HIPEC regimen was limited to 30 min. Kirstein MN [32] and Lemoine L [33] demonstrated that the response to local oxaliplatin was related to the duration of exposure. Furthermore, Levine EA et al. [34] used a HIPEC regimen lasting 120 min in their study, while Van Driel WJ [35] opted for a 90 min cisplatin-based HIPEC protocol for the treatment of ovarian cancer. Both reported increased overall survival rates with prolonged duration of HIPEC.
Regarding the cytotoxic agent used for HIPEC in the PRODIGE 7 trial, several concerns have been raised, because no standard regimen exists thus far. Hence, to increase the efficacy of intraoperative chemotherapy, many protocols have been put in place [36]. For example, the intensification of the HIPEC regimen with irinotecan has been explored in a previous study, but could not be associated with any survival benefit [11]. Furthermore, a cisplatin-based HIPEC protocol was associated with inferior long-term outcomes compared to an oxaliplatin-based regimen in an Italian multicentric study conducted by Cavaliere [18]. Thus, the most frequently used HIPEC regimens are based on oxaliplatin or mitomycin C. A Dutch series reported by Hompes et al. [37] as well as a large American retrospective study conducted by Prada-Villaverde [38] suggested no significant differences in the OS rates between the oxaliplatin-based and mytomicin C-based protocols. However, a single-center Australian study reported superior OS rates achieved by an oxaliplatin-based HIPEC regimen compared to the mytomicin C-based protocol [39]. The major criticism regarding the use of the oxaliplatin-based HIPEC protocol in the PRODIGE 7 trial is related to the extensive use of oxaliplatin in these patients before HIPEC. Previous studies [40][41] have suggested that the patients hard-treated with oxaliplatin could develop oxaliplatin resistance, resulting in decreased rates of response to a further oxaliplatin-based regimen. In the PRODIGE 7 trial, extensive oxaliplatin treatment before surgery might induce misleading results in the arm of patients treated with CRS + HIPEC, raising the question of whether a mitomycin-C based HIPEC regimen or an oxaliplatin-based HIPEC regimen prolonged to 120 min would be associated with higher survival rates in this arm.

6. Recurrent PSM

Despite the aggressive approach and curative intention, between 70% and 80% of patients with colorectal PSM treated by CRS (alone or combined with HIPEC) will develop recurrent disease [9][42]. This has led to the idea of iterative CRS and even HIPEC procedures. Several studies have suggested that in high-volume centers, the morbidity and mortality associated with these procedures are similar to those of the initial intervention [43]. This aggressive approach has led to a moderate increase in the median OS from 39 months to 42.9 months when compared to systemic treatment alone [1][43][44][45]. Although HIPEC has not been proven to be an independent risk factor for the development of postoperative complications [46], its benefit in the treatment of recurrent PSM from CRC needs further evaluation in prospective randomized controlled trials.

7. Prophylactic HIPEC in High-Risk Patients

Proactive strategies regarding high-risk patients with CRCs are still a matter of debate and no strong evidence supports their superiority versus proper surveillance. Authors such as Dominique Elias [47][48] and Serrano Del Moral [49] suggest that second-look surgery in conjunction with imagistic investigations, colonoscopies, and CEA level surveillance for high-risk patients can offer the early detection of PSM and precocious aggressive treatment. The promising results associated with prophylactic resection of target organs during the primary surgery (omentectomy, hepatic round ligament resection, appendicectomy, adnexectomy) [50] or prophylactic HIPEC administration at the time of the primary procedure for advanced tumors without PSM [51][52][53] represent the basis for some phase III randomized clinical trials evaluating the usefulness of such approaches (e.g., the ProphyloCHIP trial and COLOPEC trial). The PROPHYLOCHIP-PRODIGE 15 trial [54] evaluated the impact of second-look surgery and HIPEC vs. follow-up on 3-yr DFS of patients with resected CRC and high-risk of developing PSM (perforated primary tumor/peritoneal or ovarian metastases radically resected concomitant with CRC). The authors did not find a significant difference in the 3-yr DFS rates (44% vs. 53%, respectively; p value = 0.82). On the other hand, the COLOPEC trial [55] assessed the role of adjuvant HIPEC in preventing the occurrence of peritoneal metastases in patients with resected T4/perforated primary tumor, who received adjuvant systemic chemotherapy. There was no statistically significant difference in 18-months peritoneal DFS rates between patients treated with adjuvant systemic therapy only (76.2%) and those treated with adjuvant HIPEC and systemic therapy (80.9%; p value = 0.28). However, in both of these studies as well as in the PRODIGE 7 trial, the HIPEC protocol consisted in the administration of oxaliplatin only for 30 min. Although these trials have generated skepticism toward the usefulness of HIPEC, these results could be challenged by ongoing/future trials evaluating the different protocols of HIPEC. Until new HIPEC protocols are tested in well-designed comparative trials, this procedure should not be considered as an ineffective method [56].
Take home message: Complete CRS represents the cornerstone therapy in patients with PSM from colorectal carcinoma and a low PCI. The addition of HIPEC to complete CRS in such patients seems to have a limited benefit and this approach should be restricted to patients with a PCI > 10, operated in specialized centers, and preferably in the context of controlled trials. The current results cannot support the routine use of prophylactic HIPEC in patients operated for colorectal carcinoma with a high-risk for the development of PSM (T4/perforated primary).

This entry is adapted from the peer-reviewed paper 10.3390/medicina59020255

References

  1. Sánchez-Hidalgo, J.M.; Rodríguez-Ortiz, L.; Arjona-Sánchez, Á.; Rufián-Peña, S.; Casado-Adam, Á.; Cosano-Álvarez, A.; Briceño-Delgado, J. Colorectal peritoneal metastases: Optimal management review. World J. Gastroenterol. 2019, 25, 3484–3502.
  2. Alexandrescu, S.T.; Anastase, D.T.; Grigorie, R.T.; Zlate, C.A.; Andrei, S.; Costea, R.; Gramaticu, I.M.; Croitoru, A.E.; Popescu, I. Influence of the Primary Tumor Location on the Pattern of Synchronous Metastatic Spread in Patients with Stage IV Colorectal Carcinoma, According to the 8 th Edition of the AJCC Staging System. J. Gastrointestin Liver Dis. 2020, 29, 561–568.
  3. Segelman, J.; Granath, F.; Holm, T.; Machado, M.; Mahteme, H.; Martling, A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. 2012, 99, 699–705.
  4. Quere, P.; Facy, O.; Manfredi, S.; Jooste, V.; Faivre, J.; Lepage, C.; Bouvier, A.-M. Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study. Dis. Colon Rectum 2015, 58, 743–752.
  5. Honoré, C.; Goéré, D.; Souadka, A.; Dumont, F.; Elias, D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: A systematic review. Ann. Surg. Oncol. 2013, 20, 183–192.
  6. Rosa, F.; Galiandro, F.; Ricci, R.; Di Miceli, D.; Quero, G.; Fiorillo, C.; Cina, C.; Alfieri, S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: Analysis of short- and long-term outcomes. Langenbeck’s Arch. Surg. 2021, 406, 2797–2805.
  7. Koga, S.; Hamazoe, R.; Maeta, M.; Shimizu, N.; Kanayama, H.; Osaki, Y. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res. 1984, 44, 1840–1842.
  8. Verwaal, V.J.; van Ruth, S.; de Bree, E.; van Sloothen, G.W.; van Tinteren, H.; Boot, H.; Zoetmulder, F.A.N. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 2003, 21, 3737–3743.
  9. Elias, D.; Antoun, S.; Goharin, A.; Otmany, A.E.; Puizillout, J.M.; Lasser, P. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int. J. Surg. Investig. 2000, 1, 431–439.
  10. Elias, D.; Gilly, F.; Boutitie, F.; Quénet, F.; Bereder, J.-M.; Mansvelt, B.; Lorimier, G.; Dubè, P.; Glehen, O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J. Clin. Oncol. 2010, 28, 63–68.
  11. Quénet, F.; Goéré, D.; Mehta, S.S.; Roca, L.; Dumont, F.; Hessissen, M.; Saint-Aubert, B.; Elias, D. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann. Surg. 2011, 254, 294–301.
  12. Goéré, D.; Malka, D.; Tzanis, D.; Gava, V.; Boige, V.; Eveno, C.; Maggiori, L.; Dumont, F.; Ducreux, M.; Elias, D. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann. Surg. 2013, 257, 1065–1071.
  13. Quénet, F.; Elias, D.; Roca, L.; Goéré, D.; Ghouti, L.; Pocard, M.; Facy, O.; Arvieux, C.; Lorimier, G.; Pezet, D.; et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22, 256–266.
  14. Glehen, O.; Kwiatkowski, F.; Sugarbaker, P.H.; Elias, D.; Levine, E.A.; De Simone, M.; Barone, R.; Yonemura, Y.; Cavaliere, F.; Quenet, F.; et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J. Clin. Oncol. 2004, 22, 3284–3292.
  15. Turaga, K.; Levine, E.; Barone, R.; Sticca, R.; Petrelli, N.; Lambert, L.; Nash, G.; Morse, M.; Adbel-Misih, R.; Alexander, H.R.; et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann. Surg. Oncol. 2014, 21, 1501–1505.
  16. Yan, T.D.; Chu, F.; Links, M.; Kam, P.C.; Glenn, D.; Morris, D.L. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: Non-mucinous tumour associated with an improved survival. Eur. J. Surg. Oncol. 2006, 32, 1119–1124.
  17. da Silva, R.G.; Sugarbaker, P.H. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J. Am. Coll. Surg. 2006, 203, 878–886.
  18. Cavaliere, F.; De Simone, M.; Virzì, S.; Deraco, M.; Rossi, C.R.; Garofalo, A.; Di Filippo, F.; Giannarelli, D.; Vaira, M.; Valle, M.; et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur. J. Surg. Oncol. 2011, 37, 148–154.
  19. Van Sweringen, H.L.; Hanseman, D.J.; Ahmad, S.A.; Edwards, M.J.; Sussman, J.J. Predictors of survival in patients with high-grade peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surgery 2012, 152, 617–625.
  20. Cotte, E.; Passot, G.; Gilly, F.-N.; Glehen, O. Selection of patients and staging of peritoneal surface malignancies. World J. Gastrointest. Oncol. 2010, 2, 31–35.
  21. Yonemura, Y.; Canbay, E.; Ishibashi, H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci. World J. 2013, 2013, 978394.
  22. Benizri, E.I.; Bernard, J.-L.; Rahili, A.; Benchimol, D.; Bereder, J.-M. Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. World J. Surg. Oncol. 2012, 10, 56–58.
  23. Elias, D.; Mariani, A.; Cloutier, A.-S.; Blot, F.; Goéré, D.; Dumont, F.; Honoré, C.; Billard, V.; Dartigues, P.; Ducreux, M. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur. J. Surg. Oncol. 2014, 40, 1467–1473.
  24. Tonello, M.; Ortega-Perez, G.; Alonso-Casado, O.; Torres-Mesa, P.; Guiñez, G.; Gonzalez-Moreno, S. Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): Two different diseases. Clin. Transl. Oncol. 2018, 20, 1268–1273.
  25. Péron, J.; Mercier, F.; Tuech, J.-J.; Younan, R.; Sideris, L.; Gelli, M.; Dumont, F.; Le Roy, B.; Sgarbura, O.; Dico, R.L.; et al. The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. Surgery 2019, 165, 476–484.
  26. Massalou, D.; Benizri, E.; Chevallier, A.; Duranton-Tanneur, V.; Pedeutour, F.; Benchimol, D.; Bereder, J.-M. Peritoneal carcinomatosis of colorectal cancer: Novel clinical and molecular outcomes. Am. J. Surg. 2017, 213, 377–387.
  27. Bardou, M.; Rouland, A.; Martel, M.; Loffroy, R.; Barkun, A.N.; Chapelle, N. Review article: Obesity and colorectal cancer. Aliment. Pharmacol. Ther. 2022, 56, 407–418.
  28. Cohen, M.E.; Bilimoria, K.Y.; Ko, C.Y.; Richards, K.; Hall, B.L. Effect of subjective preoperative variables on risk-adjusted assessment of hospital morbidity and mortality. Ann. Surg. 2009, 249, 682–689.
  29. Chua, T.C.; Yan, T.D.; Saxena, A.; Morris, D.L. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality. Ann. Surg. 2009, 249, 900–907.
  30. Foster, J.M.; Sleightholm, R.; Patel, A.; Shostrom, V.; Hall, B.; Neilsen, B.; Bartlett, D.; Smith, L. Morbidity and Mortality Rates Following Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy Compared with Other High-Risk Surgical Oncology Procedures. JAMA Netw. Open 2019, 2, e186847.
  31. Cashin, P.; Sugarbaker, P.H. Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: Lessons learned from PRODIGE 7. J. Gastrointest Oncol. 2021, 12, S120–S128.
  32. Kirstein, M.N.; Root, S.A.; Moore, M.M.; Wieman, K.M.; Williams, B.W.; Jacobson, P.A.; Marker, P.H.; Tuttle, T.M. Exposure-response relationships for oxaliplatin-treated colon cancer cells. Anticancer Drugs 2008, 19, 37–44.
  33. Lemoine, L.; Thijssen, E.; Carleer, R.; Geboers, K.; Sugarbaker, P.; van der Speeten, K. Body surface area-based vs concentration-based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial. J. Surg. Oncol. 2019, 119, 999–1010.
  34. Levine, E.A.; Stewart, J.H.; Shen, P.; Russell, G.B.; Loggie, B.L.; Votanopoulos, K.I. Intraperitoneal chemotherapy for peritoneal surface malignancy: Experience with 1000 patients. J. Am. Coll. Surg. 2014, 218, 573–585.
  35. van Driel, W.J.; Koole, S.N.; Sikorska, K.; van Leeuwen, J.H.S.; Schreuder, H.W.R.; Hermans, R.H.M.; de Hingh, I.H.J.T.; van der Velden, J.; Arts, H.J.; Massuger, L.F.A.G.; et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N. Engl. J. Med. 2018, 378, 230–240.
  36. Yurttas, C.; Hoffmann, G.; Tolios, A.; Haen, S.P.; Schwab, M.; Königsrainer, I.; Königsrainer, A.; Beckert, S.; Löffler, M.W. Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer. J. Clin. Med. 2018, 7, 567.
  37. Hompes, D.; D’Hoore, A.; Wolthuis, A.; Fieuws, S.; Mirck, B.; Bruin, S.; Verwaal, V. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study. J. Surg. Oncol. 2014, 109, 527–532.
  38. Prada-Villaverde, A.; Esquivel, J.; Lowy, A.M.; Markman, M.; Chua, T.; Pelz, J.; Baratti, D.; Baumgartner, J.M.; Berri, R.; Bretcha-Boix, P.; et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J. Surg. Oncol. 2014, 110, 779–785.
  39. Leung, V.; Huo, Y.R.; Liauw, W.; Morris, D.L. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur. J. Surg. Oncol 2017, 43, 144–149.
  40. Andreou, A.; Kopetz, S.; Maru, D.M.; Chen, S.S.; Zimmitti, G.; Brouquet, A.; Shindoh, J.; Curley, S.A.; Garrett, C.; Overman, M.J.; et al. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann. Surg. 2012, 256, 642–650.
  41. de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G.; et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18, 2938–2947.
  42. Powers, B.D.; Felder, S.; Veerapong, J.; Baumgartner, J.M.; Clarke, C.; Mogal, H.; Staley, C.A.; Maithel, S.K.; Patel, S.; Dhar, V.; et al. Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. Ann. Surg. Oncol. 2020, 27, 4883–4891.
  43. Golse, N.; Bakrin, N.; Passot, G.; Mohamed, F.; Vaudoyer, D.; Gilly, F.-N.; Glehen, O.; Cotte, E. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: Postoperative and long-term results. J. Surg. Oncol. 2012, 106, 197–203.
  44. Bijelic, L.; Yan, T.D.; Sugarbaker, P.H. Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J. Surg. Oncol. 2008, 98, 295–299.
  45. Yap, D.R.Y.; Wong, J.S.M.; Tan, Q.X.; Tan, J.W.-S.; Chia, C.S.; Ong, C.-A.J. Effect of HIPEC on Peritoneal Recurrence in Peritoneal Metastasis Treated with Cytoreductive Surgery: A Systematic Review. Front. Oncol. 2021, 11, 795390.
  46. Newton, A.D.; Bartlett, E.K.; Karakousis, G.C. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A review of factors contributing to morbidity and mortality. J. Gastrointest. Oncol. 2016, 7, 99–111.
  47. Elias, D.; Honoré, C.; Dumont, F.; Ducreux, M.; Boige, V.; Malka, D.; Burtin, P.; Dromain, C.; Goéré, D. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann. Surg. 2011, 254, 289–293.
  48. Elias, D.; Goéré, D.; Di Pietrantonio, D.; Boige, V.; Malka, D.; Kohneh-Shahri, N.; Dromain, C.; Ducreux, M. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann. Surg. 2008, 247, 445–450.
  49. Del Moral, Á.S.; Viejo, E.P.; Romero, I.M.; Caravaca, G.R.; Pérez, F.P. Systematic Second-Look Surgery Plus HIPEC in Patients without Evidence of Recurrence, at High Risk of Carcinomatosis after Colorectal Cancer Resection. Cir. Esp. 2018, 96, 96–101.
  50. Sammartino, P.; Sibio, S.; Biacchi, D.; Cardi, M.; Mingazzini, P.; Rosati, M.S.; Cornali, T.; Sollazzo, B.; Atta, J.M.; Di Giorgio, A. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int. J. Color. Dis. 2014, 29, 1081–1089.
  51. Tentes, A.-A.K.; Kyziridis, D.; Kakolyris, S.; Pallas, N.; Zorbas, G.; Korakianitis, O.; Mavroudis, C.; Courcoutsakis, N.; Prasopoulos, P. Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer. Gastroenterol. Res. Pract. 2012, 2012, 506571.
  52. Baratti, D.; Kusamura, S.; Iusco, D.; Gimondi, S.; Pietrantonio, F.; Milione, M.; Guaglio, M.; Bonomi, S.; Grassi, A.; Virzì, S.; et al. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. Ann. Surg. Oncol. 2017, 24, 167–175.
  53. Sloothaak, D.A.M.; Mirck, B.; Punt, C.J.A.; Bemelman, W.A.; van der Bilt, J.D.W.; D’Hoore, A.; Tanis, P.J. Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: A systematic review. Br. J. Cancer 2014, 111, 1112–1121.
  54. Goéré, D.; Glehen, O.; Quenet, F.; Guilloit, J.M.; Bereder, J.M.; Lorimier, G.; Thibaudeau, E.; Ghouti, L.; Pinto, A.; Tuech, J.J.; et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): A randomised, phase 3 study. Lancet Oncol. 2020, 21, 1147–1154.
  55. Klaver, C.E.L.; Wisselink, D.D.; Punt, C.J.A.; Snaebjornsson, P.; Crezee, J.; Aalbers, A.G.J.; Brandt, A.; Bremers, A.J.A.; Fabry, H.F.J.; Ferenschild, F.; et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial. Lancet Gastroenterol. Hepatol. 2019, 4, 761–770.
  56. Sommariva, A.; Tonello, M.; Coccolini, F.; De Manzoni, G.; Delrio, P.; Pizzolato, E.; Gelmini, R.; Serra, F.; Rreka, E.; Pasqual, E.M.; et al. Colorectal Cancer with Peritoneal Metastases: The Impact of the Results of PROPHYLOCHIP, COLOPEC, and PRODIGE 7 Trials on Peritoneal Disease Management. Cancers 2022, 15, 165.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback